Established bioprocessing expertise creates trust, but it does not automatically transfer into advanced therapies. When customers move into cell and gene therapies, mRNA or other novel drug modalities, they look for evidence that a partner has solved problems in that specific field.
The strongest response is not broader reassurance about past experience. It is current, category-specific proof.
Why traditional bioprocessing proof points stop working
A bioprocessing company may have spent decades earning trust by helping customers manufacture one generation of therapies at scale.
But when those customers move into an entirely new treatment category, that hard-earned credibility does not necessarily follow automatically. Expertise is not inherited by default. It has to be demonstrated again within the new context.
A customer scaling a genuinely new therapy is understandably looking for a partner that has solved problems in that specific space, not simply a partner that performed exceptionally well in the previous one.
“We have been doing this for twenty years” carries less weight when those twenty years relate to a different manufacturing process, therapy type or risk profile.
The real constraint is not only manufacturing capacity
Across advanced therapy manufacturing, one of the recurring constraints is not simply access to equipment or capital. It is access to people with the specialised knowledge required to manufacture novel therapies reliably and at scale.
That shortage creates an important opportunity.
Customers are not only looking for equipment, technology or production capacity. They are also looking for partners that can compensate for an expertise gap they already recognise within their own organisation.
Bioprocessing customers need proof, not reassurance
The answer is not a reassurance campaign centred on decades of experience in general.
It is specific, concrete proof from the exact therapy categories customers are moving into.
That proof might include named partnerships, clearly described manufacturing challenges, relevant applications and measurable outcomes. It should show where the company’s expertise was applied, which problem was addressed and what changed as a result.
These examples should then be developed into a structured story that commercial teams can use consistently across sales conversations, marketing campaigns and international markets.
A broad reputation may open the conversation. Category-specific evidence is what makes the expertise credible within the new context.
The question worth asking
The most useful question is not: “How do we remind customers of our long track record?”
It is: “What specific, current proof do we have in this new therapy category, and have we told that story clearly enough?”
That shift matters. It changes the conversation from claiming credibility to demonstrating it.
How Customer Reference Marketing builds category-specific trust
This is where Customer Reference Marketing can play a strategic role.
At Living Stone, we turn genuine partnerships, technical challenges and customer outcomes into structured, reusable proof points. These stories help companies establish credibility in new categories without relying entirely on a general reputation that no longer answers the customer’s specific question.
The objective is not simply to create another customer story. It is to identify the evidence that matters most to the next customer and make it usable across marketing and sales.
Is your organisation entering a new therapy category without enough current proof?
Explore how Living Stone approaches Customer Reference Marketing and turn your newest partnerships into evidence customers can trust.
